These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
258 related articles for article (PubMed ID: 15031416)
21. Risk of peptic ulcer hospitalizations in users of NSAIDs with gastroprotective cotherapy versus coxibs. Ray WA; Chung CP; Stein CM; Smalley WE; Hall K; Arbogast PG; Griffin MR Gastroenterology; 2007 Sep; 133(3):790-8. PubMed ID: 17854591 [TBL] [Abstract][Full Text] [Related]
22. The multisystem adverse effects of NSAID therapy. James DS J Am Osteopath Assoc; 1999 Nov; 99(11 Suppl):S1-7. PubMed ID: 10643174 [TBL] [Abstract][Full Text] [Related]
23. NSAID-induced gastrointestinal damage: current clinical management and recommendations for prevention. Lanas A; Ferrandez A Chin J Dig Dis; 2006; 7(3):127-33. PubMed ID: 16808792 [TBL] [Abstract][Full Text] [Related]
24. National trends in cyclooxygenase-2 inhibitor use since market release: nonselective diffusion of a selectively cost-effective innovation. Dai C; Stafford RS; Alexander GC Arch Intern Med; 2005 Jan; 165(2):171-7. PubMed ID: 15668363 [TBL] [Abstract][Full Text] [Related]
25. The relative efficacies of gastroprotective strategies in chronic users of nonsteroidal anti-inflammatory drugs. Targownik LE; Metge CJ; Leung S; Chateau DG Gastroenterology; 2008 Apr; 134(4):937-44. PubMed ID: 18294634 [TBL] [Abstract][Full Text] [Related]
26. COX-2 inhibitors: complex association with lower risk of hospitalization for gastrointestinal events compared to traditional NSAIDs plus proton pump inhibitors. van der Linden MW; Gaugris S; Kuipers EJ; van Herk-Sukel MP; van den Bemt BJ; Sen SS; Herings RM Pharmacoepidemiol Drug Saf; 2009 Oct; 18(10):880-90. PubMed ID: 19593747 [TBL] [Abstract][Full Text] [Related]
27. Long-term NSAID use in primary care: changes over a decade and NICE risk factors for gastrointestinal adverse events. Thompson PW; Tee L; McBride J; Quincey D; Strat Liddiard G Rheumatology (Oxford); 2005 Oct; 44(10):1308-10. PubMed ID: 15972345 [TBL] [Abstract][Full Text] [Related]
28. [Non-steroidal antiinflammatory drug--management of gastrointestinal complications and inhibition of COX-2]. Tada Y; Nagasawa K Nihon Rinsho; 1999 Feb; 57(2):419-24. PubMed ID: 10078017 [TBL] [Abstract][Full Text] [Related]
29. Adverse Drug Events Involving COX-2 Inhibitors. Verrico MM; Weber RJ; McKaveney TP; Ansani NT; Towers AL Ann Pharmacother; 2003 Sep; 37(9):1203-13. PubMed ID: 12921500 [TBL] [Abstract][Full Text] [Related]
30. Prevention of anti-inflammatory drug-induced gastrointestinal damage: benefits and risks of therapeutic strategies. Lanas A; Hunt R Ann Med; 2006; 38(6):415-28. PubMed ID: 17008305 [TBL] [Abstract][Full Text] [Related]
31. Proton pump inhibitor co-therapy with nonsteroidal anti-inflammatory drugs--nice or necessary? Laine L Rev Gastroenterol Disord; 2004; 4 Suppl 4():S33-41. PubMed ID: 15580145 [TBL] [Abstract][Full Text] [Related]
32. Ulcer recurrence in high-risk patients receiving nonsteroidalanti-inflammatory drugs plus low-dose aspirin: results of a post HOC subanalysis. Goldstein JL; Huang B; Amer F; Christopoulos NG Clin Ther; 2004 Oct; 26(10):1637-43. PubMed ID: 15598480 [TBL] [Abstract][Full Text] [Related]
33. [Guideline 'NSAID use and the prevention of gastric damage']. Moens HJ; van Croonenborg JJ; Al MJ; van den Bemt PM; Lourens J; Numans ME; Ned Tijdschr Geneeskd; 2004 Mar; 148(13):604-8. PubMed ID: 15083624 [TBL] [Abstract][Full Text] [Related]
34. Determinants and sequelae associated with utilization of acetaminophen versus traditional nonsteroidal antiinflammatory drugs in an elderly population. Rahme E; Pettitt D; LeLorier J Arthritis Rheum; 2002 Nov; 46(11):3046-54. PubMed ID: 12428249 [TBL] [Abstract][Full Text] [Related]
35. Effect of antisecretory drugs and nitrates on the risk of ulcer bleeding associated with nonsteroidal anti-inflammatory drugs, antiplatelet agents, and anticoagulants. Lanas A; García-Rodríguez LA; Arroyo MT; Bujanda L; Gomollón F; Forné M; Aleman S; Nicolas D; Feu F; González-Pérez A; Borda A; Castro M; Poveda MJ; Arenas J; Am J Gastroenterol; 2007 Mar; 102(3):507-15. PubMed ID: 17338735 [TBL] [Abstract][Full Text] [Related]
36. An evidence-based approach to prescribing NSAIDs in musculoskeletal disease: a Canadian consensus. Canadian NSAID Consensus Participants. Tannenbaum H; Davis P; Russell AS; Atkinson MH; Maksymowych W; Huang SH; Bell M; Hawker GA; Juby A; Vanner S; Sibley J CMAJ; 1996 Jul; 155(1):77-88. PubMed ID: 8673987 [TBL] [Abstract][Full Text] [Related]
37. COX-2-selective inhibitors and the risk of upper gastrointestinal bleeding in high-risk patients with previous gastrointestinal diseases: a population-based case-control study. Nørgård B; Pedersen L; Johnsen SP; Tarone RE; McLaughlin JK; Friis S; Sørensen HT Aliment Pharmacol Ther; 2004 Apr; 19(7):817-25. PubMed ID: 15043523 [TBL] [Abstract][Full Text] [Related]
38. A cross-sectional retrospective assessment of anti-arthritic drugs in patients with arthritis in Korea. Lee MC; Lee S; Suh DC; Kim J; Kong SX; Curr Med Res Opin; 2003; 19(7):597-602. PubMed ID: 14606981 [TBL] [Abstract][Full Text] [Related]
39. Rheumatologists' adherence to guidelines for misoprostol use in patients at high risk for nonsteroidal antiinflammatory drug gastropathy. Cibere J; Sibley JT; Haga M J Rheumatol; 2002 Feb; 29(2):339-46. PubMed ID: 11838854 [TBL] [Abstract][Full Text] [Related]
40. Gastrointestinal safety of nonsteroidal antiinflammatory drugs and selective cyclooxygenase-2 inhibitors in patients on warfarin. Cheetham TC; Levy G; Niu F; Bixler F Ann Pharmacother; 2009 Nov; 43(11):1765-73. PubMed ID: 19809010 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]